News and Trends 12 Oct 2022 Virtual trials growth leads to Cambridge Cognition acquiring eClinicalHealth Cambridge Cognition is looking to accelerate its growth through the acquisition of eClinicalHealth Ltd (eCH). Cambridge Cognition is an active player in the central nervous system (CNS) market, supplying digital solutions to assess brain health. eCH is a full-service digital technology provider working on virtual clinical trials for three of the world’s top 10 largest […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Emergex looks to microneedle patches with Zosano Pharma acquisition Emergex Vaccines Holding Limited has acquired the assets of California-based company Zosano Pharma Corporation. Emergex is a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines. The assets acquired include intellectual property, license agreements, and manufacturing equipment. They also include Zosano’s proprietary microneedle array […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Oct 2022 Needle-free diabetes care: 7 devices that painlessly monitor blood sugar Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be […] October 7, 2022 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 6 Oct 2022 15 biotech companies shaking up the scene in Cambridge Cambridge has a large biotech scene that is starting to rival that of its U.S. namesake. Here are 15 biotech companies in Cambridge you should know about. The U.K. is home to several biotech hubs, including the golden triangle of London, Oxford and Cambridge, as well as Bristol and Stevenage. Cambridge is a small but […] October 6, 2022 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Novartis Biome UK Heart Health Catalyst 2022 winners announced Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. Lifelight and PocDoc will receive support to scale their innovative digital […] October 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data. Under the terms of the agreement, Genmab will be responsible for the […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Redx presents data confirming anti-fibrotic effects of lung disease drug Redx Pharma has announced preclinical efficacy data in immune mediated models for RXC007. The data on RXC007, its lead fibrosis asset, was presented alongside encouraging final phase 1 safety and pharmacokinetic data at the International Colloquium on Lung and Airway Fibrosis (ICLAF) on October 2 by Nicolas Guisot, research fellow at Redx Pharma. The data […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 29 Sep 2022 Baseimmune makes future-proof vaccines with AI Baseimmune is using artificial intelligence (AI) to design vaccines that can protect against future variants of infectious diseases including COVID-19 and malaria. Big data has taken off in the last decade, with dramatic improvements in bioinformatics, data science and AI. These advances allow researchers to store and handle more and more data generated by research […] September 29, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Human cells can now help scientists accelerate cure for neurodegenerative diseases Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context. UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today (September 29) with disease model, ioGlutamatergic Neurons TDP-43 and early access to its ioMicroaglia cell product. Despite research efforts and funding, bit.bio says the development […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Project to tackle biodiversity crisis using the power of DNA data and genomics launched A project to tackle the biodiversity crisis using DNA data, genomic science that will fundamentally change conservation science and policy has been launched by European experts. The new pan-European Biodiversity Genomic Europe (BGE) consortium was made public day (September 28) is leading the way with this large-scale application of genomic science. Impacts are predicted to […] September 28, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A funding back in March. The investment will allow antibody-drug conjugate (ADC) specialist Pheon to advance its lead ADC program to clinical proof-of-concept and establish of novel ADCs. The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation […] September 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email